Saturday, July 31
Shadow

Alzheimer’s drug sparks emotional battle as FDA nears deadline on whether to approve – The Washington Post

But the intravenous treatment does not cure Alzheimer’s or reverse it. It could carry a price tag as high as $50,000-a-year per patient, according to drug analysts, adding billions of dollars to the nation’s health tab. And, depending on how the FDA writes the label, millions of people could be eligible for the drug, or at least for an assessment of whether they should take it, experts say.

Leave a Reply

Your email address will not be published. Required fields are marked *